Compared to last year’s predictions, Eli Lilly’s Type 2 diabetes drug Mounjaro joined the top 10 list and secured the third spot with projected sales of nearly $20 billion. The three other GLP-1s on the list are Ozempic (No. 2), Wegovy (No. 8) and Zepbound (No. 10).
AbbVie’s Skyrizi, a biologic approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, jumped from the 10th to fifth spot.
The three that fell off the list from 2024 are Pfizer’s COVID-19 vaccine and two cancer medications, Opdivo and Gardasil.
Here are the 10 projected best-selling drugs in 2026 and their expected global sales:
1. Keytruda (Merck) — $31 billion
2. Ozempic (Novo Nordisk) — $22.3 billion
3. Mounjaro (Eli Lilly) — 19.8 billion
4. Dupixent (Sanofi) — $16.9 billion
5. Skyrizi (AbbVie) — $13.7 billion
6. Eliquis (Bristol Myers Squibb) — $13.5 billion
7. Biktarvy (Gilead) — $13.4 billion
8. Wegovy (Novo Nordisk) — $13.4 billion
9. Darzalex (Johnson & Johnson) — $13.2 billion
10. Zepbound (Eli Lilly) — $11.3 billion
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
